CDC: One-Year Survival 96.1 Percent for Male Breast Cancer
Relative survival varies by stage at diagnosis, from 98.7 to 25.9 percent for localized and distant stage, respectively.
Relative survival varies by stage at diagnosis, from 98.7 to 25.9 percent for localized and distant stage, respectively.
Researchers examined treatment patterns and prognostic factors in male breast cancer.
A meta-analysis of 222 men with nonmetastatic male breast cancer confirmed that disease stage at diagnosis remains an important prognostic factor.
Risk higher for older age, Ashkenazi descent, genetic mutations, and personal, first-degree family hx.
Draft guidance that men be included in breast cancer trials issued by the FDA.
Breast cancer survivors who received taxane-based chemotherapy for their disease are at increased risk for falls due to CIPN and treatment-associated effects on balance and gait.
Male breast cancer patients are less likely than their female counterparts to receive adjuvant hormone therapy and postlumpectomy radiation.
[Breast Cancer: Targets and Therapy] This review examines clinical characteristics of male breast cancer and best practices for long-term care with a focus on surveillance, screening, and treatment-related symptom management.
Results from the largest series of male breast cancer cases ever studied shows improvement in male survival, but not equal to that seen in women with breast cancer.
Breast cancer affects men as well as women, and the men who live with and survive breast cancer have a number of gender-specific adjustments to make.